A systematic review on the application of pharmacoepidemiology in assessing prescription drug-related adverse events in pediatrics

Current Medical Research and Opinion

Volumn 23, Issue 5, 2007, Pages 1015-1024

  Luo, Xuemei ^a,d   Cappelleri, Joseph C ^b   Frush, Karen ^c  

^a DUKE UNIVERSITY HEALTH SYSTEM   (United States)

^b PFIZER INC   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d NONE   (United States)

Author keywords

Adverse drug events; Case control; Children; Cohort; Pediatrics; Systematic review

Indexed keywords

AMPICILLIN; ANTACID AGENT; ANTIBIOTIC AGENT; ANTIDEPRESSANT AGENT; ANTIVIRUS AGENT; CEFOTAXIME; CENTRAL STIMULANT AGENT; CIPROFLOXACIN; CORTICOSTEROID; DERMATOLOGICAL AGENT; ERYTHROMYCIN; ESTROGEN; GENTAMICIN; HORMONE; ISOTRETINOIN; MEDROXYPROGESTERONE ACETATE; MORNIFLUMATE; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PROTEINASE INHIBITOR; PSYCHOTROPIC AGENT; SEX HORMONE; STEROID; VANCOMYCIN;

ACNE; ACUTE GASTROENTERITIS; ALLERGIC DISEASE; ARTHROPATHY; ASTHMA; ATOPY; BONE DENSITY; BONE DISEASE; CHILD CARE; CLINICAL TRIAL; DEPRESSION; DISEASE SEVERITY; DRUG ABUSE; DRUG EXPOSURE; DRUG FATALITY; DRUG SAFETY; FERTILITY; FRACTURE; GASTROESOPHAGEAL REFLUX; GRAM NEGATIVE SEPSIS; GROWTH DISORDER; GROWTH RETARDATION; HAY FEVER; HEMATOLOGIC DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERACTIVITY; INTUSSUSCEPTION; KIDNEY DISEASE; LIVER DISEASE; LONG TERM CARE; LONG TERM EXPOSURE; MEDICAL LITERATURE; META ANALYSIS; METHODOLOGY; NEWBORN SEPSIS; PEDIATRICS; PHARMACOEPIDEMIOLOGY; POPULATION RESEARCH; PRESCRIPTION; PYLORUS STENOSIS; REVIEW; SIDE EFFECT; SKIN MANIFESTATION; SUICIDAL IDEATION; SYSTEMATIC REVIEW; WEIGHT GAIN;

CASE-CONTROL STUDIES; CHILD; COHORT STUDIES; CONFOUNDING FACTORS (EPIDEMIOLOGY); DRUG TOXICITY; EPIDEMIOLOGIC RESEARCH DESIGN; FOLLOW-UP STUDIES; HUMANS; PATIENT SELECTION; PEDIATRICS; PHARMACOEPIDEMIOLOGY; PRESCRIPTIONS, DRUG; SAMPLE SIZE; TIME FACTORS;

EID: 34249076371     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079907X182211     Document Type: Review

References (43)

1. Department of Health and Human Services. Regulations requiring manufacturers to assess the safety and effectiveness of new drugs and biological products in pediatric patients. Washington (DC): US Government Printing Office; August, 1997
2. Griffin MR, Stein CM, Ray WA. Postmarketing surveillance for drug safety: surely we can do better. Clin Pharmacol Ther 2004;75:491-4
3. Roden DM. An underrecognized challenge in evaluating post-marketing drug safety. Circulation 2005;11:246-8
4. Ray WA. Population-based studies of adverse drug effects. New Engl J Med 2003;349:1592-4
5. Chan KA, Hernandez-Diaz S. Pharmacoepidemiology and rheumatic disorders. Rheum Dis Clin North Am 2004;30: 835-50, vii
6. Strom BL. What is pharmacoepidemiology? In: Strom BL, editor. Pharmacoepidemiology, 3rd ed. Chichester, England: John Wiley; 2000. p. 1-15
7. Hartzema AG, Porta M, Tilson HH. Pharmacoepidemiology: an introduction, 3rd ed. Cincinnati (OH): Harvey Whitney Books Company; 1998
8. Department of Health & Human Service. HHS launches new pediatric drug safety initiative. April 2002. http://www.hhs.gov/news/press/2002pres/ 20020419b.html [last accessed: January 2007]
9. Hambidge SJ, Glanz JM, France EK, et al. Safety of trivalent inactivated influenza vaccine in children 6 to 23 months old. J Am Med Assoc 2006;296:1990-7
10. Vestergaard M, Hviid A, Madsen KM, et al. MMR vaccination and febrile seizures: evaluation of susceptible subgroups and long-term prognosis. J Am Med Assoc 2004;292: 351-7
11. Celedon JC, Litonjua AA, Ryan L, et al. Lack of association between antibiotic use in the first year of life and asthma, allergic rhinitis, or eczema at age 5 years. Am J Respir Crit Care Med 2002;166:72-5
12. Chalumeau M, Tonnelier S, D'Athis P, et al. Fluoroquinolone safety in pediatric patients: a prospective, multicenter, comparative cohort study in France. Pediatrics 2003;111: e714-e719
13. Johnson CC, Ownby DR, Alford SH, et al. Antibiotic exposure in early infancy and risk for childhood atopy. J Allergy Clin Immunol 2005;115:1218-24
14. Drossou-Agakidou V, Roilides E, Papakyriakidou-Koliouska P, et al. Use of ciprofloxacin in neonatal sepsis: lack of adverse effects up to one year. Pediatr Infect Dis J 2004;23: 346-9
15. McKeever TM, Lewis SA, Smith C, et al. Early exposure to infections and antibiotics and the incidence of allergic disease: a birth cohort study with the West Midlands General Practice Research Database. J Allergy Clin Immunol 2002;109:43-50
16. Cooper WO, Griffin MR, Arbogast P, et al. Very early exposure to erythromycin and infantile hypertrophic pyloric stenosis. Arch Pediatr Adolesc Med 2002;156:647-50
17. Cullinan P, Harris J, Mills P, et al. Early prescriptions of antibiotics and the risk of allergic disease in adults: a cohort study. Thorax 2004;59:11-5
18. Clark RH, Bloom BT, Spitzer AR, et al. Empiric use of ampicillin and cefotaxime, compared with ampicillin and gentamicin, for neonates at risk for sepsis is associated with an increased risk of neonatal death. Pediatrics 2006;117:67-74
19. Bremner SA, Carey IM, DeWilde S. Early-life exposure to antibacterials and the subsequent development of hayfever in childhood in the UK: case-control studies using the General Practice Research Database and the Doctors' Independent Network. Clin Exp Allergy 2003;33:1518-25
20. Spiro DM, Arnold DH, Barbone F. Association between antibiotic use and primary idiopathic intussusception. Arch Pediatr Adolesc Med 2003;157:54-9
21. Van Houten MA, Uiterwaal CS, Heesen GJ, et al. Does the empiric use of vancomycin in pediatrics increase the risk for Gram-negative bacteremia? Pediatr Infect Dis J 2001;20:171-7
22. Barkley RA, Fischer M, Smallish L, et al. Does the treatment of attention-deficit/hyperactivity disorder with stimulants contribute to drug use/abuse? A 13-year prospective study. Pediatrics 2003;111:97-109
23. Katusic SK, Barbaresi WJ, Colligan RC, et al. Psychostimulant treatment and risk for substance abuse among young adults with a history of attention-deficit/hyperactivity disorder: a population-based, birth cohort study. J Child Adolesc Psychopharmacol 2005;15:764-76
24. Valuck RJ, Libby AM, Sills MR, et al. Antidepressant treatment and risk of suicide attempt by adolescents with major depressive disorder: a propensity-adjusted retrospective cohort study. CNS Drugs 2004;18:1119-32
25. French NP, Hagan R, Evans SF, et al. Repeated antenatal corticosteroids: effects on cerebral palsy and childhood behavior. Am J Obstet Gynecol 2004;190:588-95
26. van Staa TP, Cooper C, Leufkens HG, et al. Children and the risk of fractures caused by oral corticosteroids. J Bone Miner Res 2003;18:913-8
27. van Staa TP, Bishop N, Leufkens HG, et al. Are inhaled corticosteroids associated with an increased risk of fracture in children? Osteoporosis Int 2004;15:785-91
28. Schlienger RG, Jick SS, Meier CR. Inhaled corticosteroids and the risk of fractures in children and adolescents. Pediatrics 2004;114:469-73
29. Scholes D, LaCroix AZ, Ichikawa LE, et al. Change in bone mineral density among adolescent women using and discontinuing depot medroxyprogesterone acetate contraception. Arch Pediatr Adolesc Med 2005;159:139-44
30. Cromer BA, Stager M, Bonny A, et al. Depot medroxyprogesterone acetate, oral contraceptives and bone mineral density in a cohort of adolescent girls. J Adolesc Health 2004;35:434-41
31. Bonny AE, Ziegler J, Harvey R, et al. Weight gain in obese and nonobese adolescent girls initiating depot medroxyprogesterone, oral contraceptive pills, or no hormonal contraceptive method. Arch Pediatr Adolesc Med 2006;160:40-5
32. Venn A, Bruinsma F, Werther G, et al. Oestrogen treatment to reduce the adult height of tall girls: long-term effects on fertility. Lancet 2004;64:1513-8
33. Buchacz K, Cervia JS, Lindsey JC, et al. Impact of protease inhibitor-containing combination antiretroviral therapies on height and weight growth in HIV-infected children. Pediatrics 2001;108:E72
34. Sturkenboom M, Nicolosi A, Cantarutti L, et al. Incidence of mucocutaneous reactions in children treated with niflumic acid, other nonsteroidal antiinflammatory drugs, or nonopioid analgesics. Pediatrics 2005;116:e26-e33
35. Menniti-Ippolito F, Sagliocca L, Da Cas R, et al. Niflumic acid and cutaneous reactions in children. Arch Dis Child 2001;84:430-1
36. Chia CY, Lane W, Chibnall J, et al. Isotretinoin therapy and mood changes in adolescents with moderate to severe acne: a cohort study. Arch Dermatol 2005;141:557-60
37. Canani RB, Cirillo P, Roggero P, et al. Therapy with gastric acidity inhibitors increases the risk of acute gastroenteritis and community-acquired pneumonia in children. Pediatrics 2006;117:e817-e820
38. Wong IC, Murray ML. The potential of UK clinical databases in enhancing paediatric medication research. Br J Clin Pharmacol 2005;59:750-5
39. Martin A, Van Hoof T, Stubbe D, et al. Multiple psychotropic pharmacotherapy among child and adolescent enrollees in Connecticut Medicaid Managed Care. Psychiatric Services 2003;54:72-7
40. Safer DJ, Zito JM, DosReis S. Concomitant psychotropic medication for youths. Am J Psychiatry 2003;160:438-49
41. Juurlink DN, Mamdani MM, Kopp A, et al. A population-based assessment of the potential interaction between serotonin-specific reuptake inhibitors and digoxin. Br J Clin Pharmacol 2005;59:102-7
42. Juurlink DN, Mamdani M, Kopp A, et al. Drug-drug interactions among elderly patients hospitalized for drug toxicity. J Am Med Assoc 2003;289:1652-8
43. Schirm E, Tobi H, de Jong-van den Berg LT. Unlicensed and off label drug use by children in the community: cross-sectional study. Br Med J 2002;324:1312-3